Triple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer (BC)
with a poor prognosis. Current treatment options are limited to surgery, adjuvant …

Breast cancer is the second leading cause of death for women worldwide. The
heterogeneity of this disease presents a big challenge in its therapeutic management …

Tumour heterogeneity and a long-standing paucity of effective therapies other than
chemotherapy have contributed to triple-negative breast cancer (TNBC) being the subtype …

Triple negative breast cancer (TNBC) is characterized by the lack of estrogen and
progesterone receptor expression and lacks HER2 overexpression or gene amplification. It …

Cancer is a severe public health issue that is a leading cause of mortality globally. It is also
an impediment to improving life expectancy worldwide. Furthermore, the global burden of …

Due to the advantages in efficacy and safety compared with traditional chemotherapy drugs,
targeted therapeutic drugs have become mainstream cancer treatments. Since the first …

The therapeutic effect of highly malignant triple negative breast cancer (TNBC) is negatively
affected by the formation of tumor cell resistant clone and the severe toxicity of …

Summary Background The PI3K/AKT and androgen-receptor pathways are dysregulated in
metastatic castration-resistant prostate cancers (mCRPCs); tumours with functional PTEN …

Breast cancer (BC) is the most frequent cancer diagnosed in women worldwide. This
heterogeneous disease can be classified into four molecular subtypes (luminal A, luminal B …

Triple‑negative breast cancer (TNBC) accounts for 10‑15% of all breast cancer cases.
TNBCs lack estrogen and progesterone receptors and express low levels of HER2, and …